Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib + Hydroxychloroquine in KRAS-mutated BTC
NCT04566133Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Feb 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trametinib, hydroxychloroquine in biliary tract carcinoma (BTC), sponsored by National Cancer Institute. Started Feb 2022; status: terminated.
02
Drugs
trametinibhydroxychloroquine
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT04566133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04566133.